ConductScience.org, home

Trial · NCT07009457

A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

NCT07009457, Phase 1, Active not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer. Trials, record NCT07009457. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07009457

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
NCT number
NCT07009457
Status
Active not recruiting
Phases
Phase 1
Enrollment
24 participants, actual
Lead sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions
Widespread Small Cell Lung Cancer
Interventions
SHR-1316 (sc) Injection, SHR-1316 Injection, Carboplatin Injection, Etoposide Injection
First posted
2025-06-06
Last updated
2026-06-30

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimarySHR-1316 serum trough concentration (Ctrough)Day1 pre-dose to Day28.
PrimaryArea under the concentration curve from time 0 to 21 days for SHR-1316 (sc) (AUC0-21d)Day1 pre-dose to Day21.
PrimaryArea under the concentration curve from time 0 to 28 days for SHR-1316 (sc) (AUC0-28d)Day1 pre-dose to Day28.
SecondaryMaximum Concentration of SHR-1316 (sc) (Cmax)Day1 pre-dose to Day28.
SecondaryTime to maximum plasma concentration (Tmax)Day1 pre-dose to Day28.
SecondaryTerminal half-life (t1/2)Day1 pre-dose to Day28.
SecondaryIncidence and severity of adverse events (AEs)About 2 years.
SecondaryObjective Response Rate (ORR)About 2 years.
SecondaryDuration of Relief (DoR)About 1.5 years.
SecondaryDisease Control Rate (DCR)About 2 years.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07009457

GET https://conductscience.org/api/trials/v1/NCT07009457/registered